This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aarons L (1991). Population pharmacokinetics: Theory and practice. Br J Clin Pharmacol, 32:669–670.
Amisaki T and Tatsuhara T (1988). An alternative two stage method via the EM-algorithm for the estimation of population pharmacokinetic parameters. J Pharmacobto-Dyn, 11:335–348.
Balant LP (1985). Dosage des médicaments au cours des essais de phase III et de phase IV. Méd Hyg, 43:2470–2473.
Balant LP (1993). Blood concentrations measurement in clinical trials. Appl Clin Trials, 2:44–93.
Balant LP and Bechtel P (1994). Inter-ethnic differences in dose response studies. In: Walker SR, Lumley CE and McAuslane JAN (eds) The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. Kluwer Academic Publishers, Lancaster, pp. 27–48
Balant LP, Gundert-Remy U, Boobis AR and von Bahr Ch (1989). Relevance of genetic polymorphism in drug metabolism in the development of new drugs. Eur J Clin Pharmacol, 36:551–554.
Balant LP, Roseboom H and Gundert-Remy U (1990). Pharmacokinetic criteria for drug research and development. In: Testa B (ed.) Advances in Drug Research. Academic Press, London, pp. 1–139.
Beal SL and Sheiner LB (1980). The NONMEM system. Am Stat, 34:118–119.
Ebelin ME, Steimer JL, Laplanche R and Niederberger W (1992). An evaluation of population pharmacokinetics during drug development: Experiences with graphical exploratory analysis for isradipine and tropisetron. In: Rowland M and Aarons L (eds) New Strategies in Drug Development and Clinical Evaluation: The Population Approach. Commission of the European Communities (Coordinated Action COST B1), Luxembourg, pp. 131–141.
Gex-Fabry M, Balant-Gorgia AE, Balant LP and Garrone G (1990). Clomipramine metabolism: Model based analysis of variability factors from drug monitoring data. Clin Pharmacokin, 19:241–255.
Gundert-Remy U (1992). Population approach in pharmacokinetics and pharmacodynamics - Views within regulatory agencies: Europe. In: Rowland M and Aarons L (eds) New Strategies in Drug Development and Clinical Evaluation: The Population Approach.Commission of the European Communities (Coordinated Action COST B1), Luxembourg, pp. 153–156.
Kalow W (1982). Ethnic differences in drug metabolism. Clin Pharmacokin, 7:373–400.
Kalow W (1992). Pharmacoanthropology and the genetics of drug metabolism. In: Kalow W (ed.) Pharmacogenetics of Drug Metabolism. Pergamon Press, New York, pp. 865–877.
Laplanche R, Fertil B, Nüesch E, Jais JP, Niederberger W and Steimer JL (1991). Exploratory analysis of population pharmacokinetic data from clinical trials with application to isradipine. Clin Pharmacol Ther, 50:39–54.
Lindholm A, Welsch M, Alton C and Kahan BD (1992). Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability. Clin Pharmacol Ther, 52, 359–371.
Lindstrom MJ and Bates DM (1990). Nonlinear mixed effects models for repeated measures data. Biometrics, 46:673–687.
Mallet A (1986) A maximum likelihood estimation method for random coefficient regression models. Biometrika, 73:645–656.
Mallet A, Mentré F, Steamer JL and Lokiec F (1988). Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. J Pharmacokin Biopharm, 16:311–327.
Peck CC (1992). Population approach in pharmacokinetics and pharmacodynamics: FDA view. In: Rowland M and Aarons L (eds) New Strategies in Drug Development and Clinical Evaluation: The Population Approach. Commission of the European Communities (Coordinated Action COST B1), Luxembourg, pp. 157–168.
Peck CC and co-authors (1992). Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther, 51:465–473.
Racine-Poon A and Smith AFM (1990). Population models. In: Berry DA (ed.), Statistical Methodology in the Pharmaceutical Sciences. Marcel Dekker, New York, pp. 139–162.
Sheiner LB (1992). Population approach in drug development: Rationale and basic concepts. In: Rowland M and Aarons L (eds) New Strategies in Drug Development and Clinical Evaluation: The Population Approach. Commission of the European Communities (Coordinated Action COST B1), Luxembourg, pp. 13–27.
Sheiner LB, Benet LZ (1985). Premarketing observational studies of population pharmacokinetics of new drugs. Clin Pharmacol Ther, 38:481–487.
Temple R (1983). Discussion paper on the testing of drugs in the elderly, Washington, DC: Memorandum of the Food and Drug Administration of DHHS.
Temple R (1985). Food and Drug Administration’s guidelines for clinical testing of drugs in the elderly. Drug Information J, 19:483–486.
Vozeh S (1992). Applications of population approach to clinical pharmacokinetics and validation of results. In: Rowland M and Aarons L (eds) New Strategies in Drug Development and Clinical Evaluation: The Population Approach. Commission of the European Communities (Coordinated Action COST B1), Luxembourg, pp. 107–120.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Balant, L., Gex-Fabry, M., Balant-Gorgia, A. (1994). Implications for the design and interpretation of Phase III clinical trials. In: Walker, S., Lumley, C., McAuslane, N. (eds) The Relevance of Ethnic Factors in the Clinical Evaluation of Medicines. CMR Workshop Series. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1420-2_17
Download citation
DOI: https://doi.org/10.1007/978-94-011-1420-2_17
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4621-3
Online ISBN: 978-94-011-1420-2
eBook Packages: Springer Book Archive